Acrivon Therapeutics is a clinical-stage oncology company focused on developing targeted therapies to improve the lives of cancer patients. Operating at the frontier of proteomics, Acrivon employs its proprietary precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop a robust drug pipeline. The AP3 platform generates OncoSignature companion diagnostics, which are designed to accurately identify patients whose tumors are predicted to be sensitive to Acrivon's drug candidates. This approach aims to revolutionize precision oncology drug development and treatment by ensuring that therapies are matched with patients who are most likely to benefit, regardless of underlying genetic tumor alterations.

Acrivon serves patients suffering from various types of cancer, aiming to provide more effective and personalized treatment options. The company operates within the precision oncology market, which focuses on tailoring medical treatment to the individual characteristics of each patient's disease. Acrivon's business model involves the development and commercialization of its proprietary therapies and companion diagnostics, generating revenue through the sale of these products and potentially through partnerships and collaborations with other pharmaceutical companies.

Keywords: precision oncology, proteomics, targeted therapies, cancer treatment, clinical-stage, drug development, companion diagnostics, personalized medicine, AP3 platform, OncoSignature.